Using older mice, scientists identified a key mediator of increased breast cancer metastasis, offering a potential therapeutic target for older patients.
Renaming PCOS to polyendocrine metabolic ovarian syndrome (PMOS) marks a major shift toward more comprehensive and lifelong care for the multi-systemic condition.